Industry & Policy News

[WVU Today] West Virginia University (WVU) scientists are building on their research to alter the immune system by inhibiting a certain enzyme responsible for the progression of pancreatic cancer. The three-year project is supported by a $330,000 Career Development Award for Pancreatic Cancer Research from the Lustgarten Foundation and American Association for Cancer Research.

[Johnson & Johnson] Johnson & Johnson announced that the US FDA has approved TREMFYA® for the treatment of adults with moderately to severely active ulcerative colitis.

[Neurona Therapeutics] Neurona Therapeutics announced that the California Institute for Regenerative Medicine (CIRM) has awarded a $3.8M grant to support the development of a next generation neural cell therapy candidate.

[STAT News] Powerful House lawmakers from both parties are skeptical of the Food and Drug Administration’s pitch to start collecting fees from e-cigarette companies, similar to how the agency assesses them on tobacco firms.

[Fibrobiologic, Inc.] FibroBiologics, Inc. announced the filing of a patent application with the United States Patent Office covering the use of fibroblast cell-based technology in generating three-dimensional hemopoietic organoids that can give rise to immune cells.

[Imperial College University] More than £91 million was donated to Imperial during the 2023/24 financial year – the most ever to have been given in a single year. This transformational amount will support groundbreaking research initiatives, state-of-the-art facilities, and a range of scholarships, fellowships and academic posts.